Although endometrial cancer (EC) is the most common gynecologic cancer in women, the majority of the cancers are early stage. Since the overall 5-year survival rate for patients with stage I disease is 86%, the number of women who have survived EC represents an enlarging and ever-increasing population of cancer survivors (1). The question of estrogen replacement therapy (ERT) for the relief of menopausal symptoms, prevention of osteoporosis, and colon cancer becomes evermore relevant for this group of women. Because of shared epidemiologic and genetic risk factors, woman with EC may also be at increased risk for breast cancer, thus further complicating considerations for ERT or hormone replacement theraphy (HRT) in these patients.
